Cardiac Involvement in the Antiphospholipid Syndrome

Handbook of Systemic Autoimmune Diseases

Volumn 1, Issue , 2003, Pages 213-225

  Erkan, Doruk ^a   Roman, Mary J ^b   Tenedios, Felicia ^a   Lockshin, Michael D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7044261414     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(03)01014-6     Document Type: Review

References (68)

1. Afek A., Shoenfeld Y., Manor R., Goldberg I., Ziporen L., George J., Polak-Charcon S., Amigo M.C., Garcia-Torres R., Segal R., and Kopolovic J. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8 (1999) 502
2. Ames P.R.J., Margarita A., Delgado Alves J., Tommasino C., Iannaccone L., and Brancaccio V. Anticardiolipin antibody titer and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11 (2002) 208
3. Amital H., Langevitz P., Levy Y., Afek A., Goldberg I., Pras M., Livneh A., and Shoenfeld Y. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin. Exp. Rheumatol. 17 (1999) 99
4. Asherson R.A., Khamashta M.A., Ordi-Ros J., Derksen R.H., Machin S.J., Barquinero J., Outt H.H., Harris E.N., Vilardell-Torres M., and Hughes G.R. The 'primary' antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68 (1989) 366
5. Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., Lim K., Munoz-Rodriguez F.J., Levy R.A., Boue F., Rossert J., and Ingelmo M. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 (1998) 195
6. Bili A., Moss A.J., Francis C.W., Zareba W., Watelet L.F., and Sanz I. Antiphospholipid antibodies and recurrent coronary events-a prospective study of 1150 patients. Circulation 102 (2000) 1258 This study demonstrated that anticardiolipin antibodies are independent risk factors for recurrent cardiac events in patients with myocardial infarction
7. Brenner B., Blumenfeld Z., Markiewicz W., and Reisner S.A. Cardiac involvement in patients with primary antiphospholipid syndrome. J. Am. Coll. Cardiol. 18 (1991) 931
8. Brey R., and Levine S.R. APL and the brain: treatment. Lupus 11 (2002) 2002 (Abstract)
9. Cervera R., Khamashta M.A., Font J., Reyes P.A., Vianna J.L., A, Amigo M.C., Asherson R.A., Azqueta M., and Pare C. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome. Lupus 1 (1991) 43
10. Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J. Autoimmun. 15 (2000) 123 A summary of echocardiographic findings, pathogenesis, and clinical manifestations of antiphospholipid antibody-related valvulopathies
11. Ciocca R.G., Choi J., and Graham A.M. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am. J. Surg. 170 (1995) 198
12. Coudray N., de Zuttere D., Bletry O., Piette J.C., Wechsler B., Godeau P., Pourny J.C., Lecarpentier Y., and Chemla D. M mode and doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br. Heart J. 74 (1995) 531
13. Cuadrado M.J., and Hughes G.R.V. Hughes (antiphospholipid) syndrome. Clinical features. Rheum. Dis. Clin. North Am. 27 (2001) 507
14. De Caterina R., d'Ascanio A., Mazzone A., Gazzetti P., Bernini W., Neri R., and Bombardieri S. Prevalence of anticardiolipin antibodies in coronary artery disease. Am. J. Cardiol. 65 (1990) 922
15. Ducart A.R., Collard E.L., Osselaer J.C., Broka S.M., Eucher P.M., and Joucken K.L. Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J. Cardiothorac. Vasc. Anesth. 11 (1997) 878
16. East C.J., Clements F., Mathew J., and Slaughter T.F. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth. Analg. 90 (2000) 1098
17. Erkan D., Yazici Y., Sobel R., and Lockshin M. Primary antiphospholipid syndrome: functional outcome after 10 years. J. Rheumatol. 27 (2000) 2817
18. Erkan D., Merrill J.T., Yazici Y., Sammaritano L., Buyon J.P., and Lockshin M.D. High thrombosis rate after fetal loss in antiphospholipid syndrome. Effective prophylaxis with aspirin. Arthritis Rheum. 44 (2001) 1466
19. Erkan D., Yazici Y., Peterson M., Sammaritano L., and Lockshin M.D. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 41 (2002) 924
20. Erkan D., Erel H., Yazici Y., and Prince M.R. The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J. Rheumatol. 29 (2002) 2658
21. Erkan D., Sammaritano L., and Lockshin M.D. Management of the difficult aspects of antiphospholipid syndrome. In: Asherson R.A., Cervera R., Piette J.C., and Shoenfeld Y. (Eds). Antiphospholipid Syndrome II (2002), Elsevier, Amsterdam 353
22. Erkan D., Leibowitz E., Berman J., and Lockshin M.D. Perioperative medical management of antiphospholipid syndrome: Hospital for Special Surgery experience, review of the literature and recommendations. J. Rheumatol. 29 (2002) 843 When an Antiphospholipid Syndrome (APS) patient undergoes a surgical procedure, serious perioperative complications may occur despite prophylaxis. This paper summarizes strategies that may guide physicians in their preoperative, intraoperative, and postoperative management of APS patients
23. Espinola-Zavaleta N., Vargas-Barron J., Colmenares-Galvis T., Cruz-Cruz F., Romero-Cardenas A., Keirns C., and Amigo M.C. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am. Heart J. 137 (1999) 973
24. Espinosa G., Cervera R., Font J., Garcia-Carrasco M., Battagliotti C., and Ingelmo M. Cardiac and pulmonary manifestations in the antiphospholipid syndrome. In: Asherson R.A., Cervera R., Piette J.C., and Shoenfeld Y. (Eds). Antiphospholipid Syndrome II-Autoimmune Thrombosis (2002), Elsevier, Amsterdam 169
25. Font J., Lopez-Soto A., Cervera R., Balasch J., Pallares L., Navarro M., Bosch X., and Ingelmo M. The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 9 (1991) 69
26. Galve E., Candell-Riera J., Pigrau C., Permanyer-Miralda G., Garcia-Del-Castillo H., and Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N. Engl. J. Med. 319 (1988) 817
27. Galve E., Ordi J., Barquinero J., Evangelista A., Vilardell M., and Soler-Soler J. Valvular heart disease in the primary antiphospholipid syndrome. Ann. Intern. Med. 116 (1992) 293
28. Garcia-Torres R., Amigo M.C., de la Rosa A., Moron A., and Reyes P.A. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 5 (1996) 56
29. Hamsten A., Norberg R., Bjorkholm M., de Faire U., and Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1 8473 (1986) 113
30. Hasnie A.M., Stoddard M.F., Gleason C.B., Wagner S.G., Longaker R.A., S, and Harris E.N. Diastolic dysfunction is a feature of the antiphospholipid syndrome. Am. Heart J. 129 (1995) 1009
31. Hogan W.J., McBane R.D., Santrach P.J., Plumhoff E.A., Oliver W.C.J., Schaff H.V., Rodeheffer R.J., Edwards W.D., Duffy J., and Nichols W.L. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin. Proc. 75 (2000) 971
32. Hojnik M., George J., Ziporen L., and Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93 (1996) 1579
33. Kattwinkel N., Villanueva A.G., Labib S.B., Aretz H.T., Walek J.W., Burns D.L., and Klenz J.T. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann. Intern. Med. 116 12 Pt 1 (1992) 974
34. Khamashta M.A., Cervera R., Asherson R.A., Font J., Gil A., Coltart D.J., Vazquez J.J., Pare C., Ingelmo M., and Oliver J. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335 8705 (1990) 1541
35. Kupferwasser L.I., Hafner G., Mohr-Kahaly S., Erbel R., Meyer J., and Darius H. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J. Am. Coll. Cardiol. 33 (1999) 1365
36. Lagana B., Baratta L., Tubani L., Golluscio V., Delfino M., and Rossi Fanelli F. Myocardial infarction with normal coronary arteries in a patient with primary antiphospholipid syndrome-case report and literature review. Angiology 52 (2001) 785
37. Lee R., and Frenkel E.P. Hyperhomocysteinemia and thrombosis. Hematol. Oncol. Clin. North Am. 17 (2003) 85
38. Leung W.H., Wong K.L., Lau C.P., Wong C.K., and Liu H.W. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am. J. Med. 89 (1990) 411
39. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N. Engl. J. Med. 346 (2002) 752
40. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., Alam Z., and Carey J.L. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28 (1997) 1660
41. Lockshin M.D., Salmon J.E., and Roman M.J. Atherosclerosis and lupus: a work in progress. Arthritis Rheum. 44 (2001) 2215-2217
42. Lockshin M.D. Antiphopholipid antibody syndrome. In: Ruddy S., Harris E.D., and Sledge C.B. (Eds). Kelley's Textbook of Rheumatology (2001), Saunders Company, Philadelphia 1145
43. The 10th International Congress on antiphospholipid antibodies was held in Taormina, Sicily, Italy between September 29 and October 3, 2002. A Cardiac Committee reviewed cardiac involvement in the Antiphospholipid Syndrome and published treatment recommendations. Lockshin M.D., Tenedios F., Petri M., McCarty G., Forastiero R., Krilis S., Tincani A., Erkan D., Khamashta M.A., and Shoenfeld Y. Cardiac disease in antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12 (2003) 518
44. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A.J., Jansen-McWilliams L., D'Agostino R.B., and Kuller L.H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145 (1997) 408
45. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P., and Kuller L.H. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis. Rheum. 42 (1999) 51
46. Matsuyama K., Ueda Y., Ogino H., Sugita T., Matsubayashi K., Nomoto T., Yoshimura S., and Yoshioka T. Aortic valve replacement for aortic regurgitation in a patient with primary antiphospholipid syndrome. Jpn. Circ. J. 63 (1999) 725
47. Meroni P.L., Raschi E., Testoni C., Tincani A., and Balestrieri G. Antiphospholipid antibodies and the endothelium. Rheum. Dis. Clin. 27 (2001) 587
48. Meroni P.L., Raschi E., and Testoni C. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44 (2001) 2870
49. Nesher G., Ilany J., Rosenmann D., and Abraham A.S. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Sem. Arthritis Rheum. 27 (1997) 27 The pathogenesis, prevalence (including a meta-analysis), clinical presentation, and treatment options of Antiphospholipid Syndrome-related valvular dysfunction were discussed
50. Nihoyannopoulos P., Gomez P., Joshi M., Loizou S., Walport M.J., and Oakley C.M. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 82 (1990) 369
51. O'Neill D., Magaldi J., Dobkins D., and Greco T. Dissolution of intracardiac mass lesions in the primary antiphospholipid syndrome. Arch. Intern. Med. 155 (1995) 325-327
52. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun. 15 (2000) 145
53. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum. Dis. Clin. North Am. 26 (2000) 199
54. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9 (2000) 170
55. Puurunen M., Manttari M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., Vaarala O., Aho K., and Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154 (1994) 2605
56. Roldan C.A., Shively B.K., Lau C.C., Gurule F.T., Smith E.A., and Crawford M.H. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J. Am. Coll. Cardiol. 20 (1992) 1127
57. Roman M.J., Salmon J.E., Sobel R., Lockshin M.D., Sammaritano L., Schwartz J.E., and Devereux R.B. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am. J. Cardiol. 87 (2001) 663
58. Ruiz-Irastorza G., Khamashta M.A., Hunt B.J., Escudero A., Cuadrado M.J., and Hughes G.R. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Arch. Intern. Med. 162 (2002) 1164
59. Seelos K., Caputo G.R., Carrol C.L., Hricak H., and Higgins C.B. Cine gradient refocused (GRE) echo imaging of intravascular masses: differentiation between tumor and nontumorous thrombus. J. Comput. Assist. Tomogr. 16 (1992) 169
60. Shahian D.M., Labib S.B., and Schneebaum A.B. Etiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus. J. Card. Surg. 10 (1995) 133
61. Sheikh F., Lechowicz A., Setlur R., Rauch A., and Dunn H. Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. Cardiothorac. Vasc. Anesth. 11 (1997) 764
62. Skyrme-Jones R.A., Wardrop C.A., Wiles C.M., and Fraser A.G. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J. Am. Soc. Echocardiogr. 8 (1995) 251
63. Sletnes K.E., Smith P., Abdelnoor M., Arnesen H., and Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 339 8791 (1992) 451-453
64. Turiel M., Muzzupappa S., Gottardi B., Crema C., Sarzi-Puttini P., and Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 9 (2000) 406
65. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R., Triplett D.A., and Khamashta M.A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42 (1999) 1309 The first published international consensus statement on the preliminary classification criteria for definite antiphospholipid syndrome
66. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 8925 (1994) 793
67. Yoshida M., Sasako Y., Kobayashi J., Minatoya K., Bando K., and Kitamura S. Mitral valve plasty in systemic lupus erythematosus in the setting of antiphospholipid syndrome. Jpn. J. Thorac. Cardiovasc. Surg. 48 (2000) 391
68. Ziporen L., Goldberg I., and Arad M. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5 (1996) 196